In this study, we focused on hypoxia-induced cisplatin resistance, particularly on the interaction between p53 and HIF-1α, to restore treatment response in a panel of NSCLC cell lines with different p53 status using the compound APR-246 (PRIMA-1MET). Here, TP53 is linked to non-small cell lung carcinoma.